5-HT receptors expressed throughout the human body are targets for established
therapeutics and various drugs in development. Their diversity of structure and function …

Psychotic depression was initially considered to be at one end of a continuum of severity of
major depression. Subsequent experience demonstrated that psychosis is an independent …

Objectives: To provide advice and guidance regarding the management of mood disorders,
derived from scientific evidence and supplemented by expert clinical consensus to formulate …

Objectives: To provide guidance for the management of mood disorders, based on scientific
evidence supplemented by expert clinical consensus and formulate recommendations to …

Introduction: Antipsychotic-induced weight-gain (AIWG) is a very important, yet often
neglected side-effect in the treatment with first and second generation antipsychotics. AIWG …

We review recent developments in the acute and long-term treatment of bipolar disorder and
identify promising future routes to therapeutic innovation. Overall, advances in drug …

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C,
MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN …

Objective: In a phase 3 randomized double-blind placebo-controlled study, the authors
investigated the efficacy and safety of 42 mg/day of lumateperone in patients with bipolar I or …

Schizophrenia and depression are heterogeneous disorders. The complex
pathomechanism of the diseases imply that medication responses vary across patients …

The British Association for Psychopharmacology guidelines specify the scope and targets of
treatment for bipolar disorder. The third version is based explicitly on the available evidence …